Bachem Holding AG Stock Swiss Exchange
Equities
BANB
CH0012530207
Biotechnology & Medical Research
Sales 2024 * | 620M 679M | Sales 2025 * | 811M 888M | Capitalization | 5.99B 6.56B |
---|---|---|---|---|---|
Net income 2024 * | 127M 139M | Net income 2025 * | 160M 175M | EV / Sales 2024 * | 9.56 x |
Net cash position 2024 * | 64.89M 71.05M | Net Debt 2025 * | 74.85M 81.95M | EV / Sales 2025 * | 7.48 x |
P/E ratio 2024 * |
49.9
x | P/E ratio 2025 * |
37.8
x | Employees | 2,006 |
Yield 2024 * |
1.08% | Yield 2025 * |
1.17% | Free-Float | 94.31% |
Latest transcript on Bachem Holding AG
Managers | Title | Age | Since |
---|---|---|---|
Thomas Meier
CEO | Chief Executive Officer | 56 | 18-12-31 |
Alain Schaffter
DFI | Director of Finance/CFO | 47 | 21-01-31 |
Ralph Schönleber
CTO | Chief Tech/Sci/R&D Officer | - | 02-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Grogg
BRD | Director/Board Member | 82 | - |
Kuno Sommer
CHM | Chairman | 68 | 12-04-24 |
Director/Board Member | 51 | 11-04-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 18 M€ | +4.00% | - |
1st Jan change | Capi. | |
---|---|---|
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |